ca. 2 Minuten

Lithuania: INVEST MTEP R&D grants (02-118-K) — open to 8 February 2027

Veröffentlicht von · AE Valley / SupraTix GmbH
Veröffentlicht am

Lithuania: INVEST MTEP R&D grants (02-118-K) — open to 8 February 2027

Lithuania’s open INVEST MTEP call 02-118-K allocates €40.77m across two R&D activities in Central and Western Lithuania. Applications close 8 February 2027 at 17:00; the portal does not state a timezone. See the linked call rules for activity-specific eligibility.

Call status and deadline

The Lithuanian EU Investment portal lists INVEST MTEP (call 02-118-K) as open. Applications are accepted from 7 October 2026 at 14:00 through 8 February 2027 at 17:00. The portal does not specify the deadline timezone. The call uses competitive selection and provides grants. Total allocation: €40,773,375.

Two funding activities

  • Foreign-investor R&D and technology transfer (05-001-01-05-07-10-02): for a foreign-investor SME, or a large enterprise cooperating with an SME; project cap €1,500,000.
  • Advanced-innovator product development (05-001-01-05-07-06-02): for an SME or a large enterprise cooperating with an SME, subject to the advanced-innovator definition; new product development, researchers in business R&D, intellectual property, pilot production and market preparation; project cap €1,800,000.

Key conditions

Both activities are located in Central and Western Lithuania. For the advanced-innovator product-development activity, the call detail requires at least three operating financial years, cumulative sales of at least €300,000 over the last three financial years, and R&D expenditure of at least €60,000 over that period.

The product-development activity must address at least one Health Technologies and Biotechnology S3 theme: molecular technologies for medicine or biopharma; advanced medical engineering for early diagnosis or treatment; or safe food and sustainable agrobiological resources. This is a specific thematic eligibility gate.

Funding rates and costs

Funding can cover up to 80% of eligible R&D activity and up to 85% of eligible patenting and market-preparation activity. The stated minimum own contribution is 20% for R&D and 15% for patenting and market preparation. Projects may run for up to 24 months. Software licence acquisition is listed as ineligible.

Official sources

Checked 9 October 2026. Applicants should review the current call documents and confirm all activity-specific conditions before applying.





SupraTix GmbH oder Partnergesellschaften - Alle Rechte vorbehalten.

Copyright © 2016–2026